Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Partners With Seattle Genetics On Lymphoma Candidate In Pivotal Trials

This article was originally published in The Pink Sheet Daily

Executive Summary

Days after losing Roche/Genentech as a partner for dacetuzumab, Seattle Genetics signs Takeda as a partner for a late-stage antibody-drug conjugate.

You may also be interested in...



Deal Watch: Oncology A Recurring Theme In Recent Spate Of Transactions

TetraLogic uses cash from its recent IPO to bring form to its oncology pipeline via the acquisition of Shape Pharmaceuticals. Also, GlaxoSmithKline becomes the latest big pharma to partner with MD Anderson Cancer Center’s Moon Shots program and Mersana will collaborate with Takeda on antibody-drug conjugates for cancer.

Velcade’s New SubQ Formulation Means More To Takeda Than An Incremental Advance

Market leading multiple myeloma treatment Velcade’s newly approved subcutaneous formulation offers greatly reduced rates of peripheral neuropathy compared to the standby intravenous formula and with similar survival data, a new marketing advantage in the face of next-generation challenges.

Seattle Genetics Will Test Oncology Pricing Acceptance With Adcetris

Now that Seattle Genetics Inc. is making the transition into a commercial drug company with the FDA approval of its oncologic Adcetris, its success will depend on how effectively it can convince payers, patients and physicians that Adcetris is worth its premium price and how well it can extend the drug’s reach to larger patient markets.

Related Content

Topics

UsernamePublicRestriction

Register

PS068881

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel